Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Equipment, Supplies & Distribution
Sub-Industry: N/A
Symbol: NASDAQ:XENT
CUSIP: N/A
Web: www.intersectent.com

Capitalization:

Market Cap: $893.18 million
Outstanding Shares: 29,189,000

Average Prices:

50 Day Moving Avg: $30.07
200 Day Moving Avg: $26.45
52 Week Range: $7.65 - $33.25

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -78.46
P/E Growth: -2.35

Sales & Book Value:

Annual Revenue: $87.16 million
Price / Sales: 10.25
Book Value: $3.88 per share
Price / Book: 7.89

Profitability:

EBITDA: ($19,710,000.00)
Net Margins: -22.94%
Return on Equity: -17.60%
Return on Assets: -15.64%

Debt:

Current Ratio: 9.81%
Quick Ratio: 9.17%

Misc:

Average Volume: 266,775 shs.
Beta: 0.72
Short Ratio: 2.34

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) issued its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.11. The company had revenue of $24 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The company's quarterly revenue was up 24.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.21) earnings per share. View Intersect ENT's Earnings History.

When will Intersect ENT make its next earnings announcement?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Intersect ENT.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 analysts have issued 12-month target prices for Intersect ENT's shares. Their predictions range from $14.00 to $40.00. On average, they anticipate Intersect ENT's stock price to reach $27.11 in the next year. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (10/5/2017)
2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Some companies that are related to Intersect ENT include CONMED Corporation (CNMD), MiMedx Group (MDXG), Asante Solutions (PUMP), OraSure Technologies (OSUR), Orthofix International N.V. (OFIX), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), AtriCure (ATRC), CryoLife (CRY), Meridian Bioscience (VIVO), Landauer (LDR), Consort Medical plc (CSRT), STAAR Surgical Company (STAA), Transenterix (TRXC), Transenterix (TRXC), Invacare Corporation (IVC), Exactech (EXAC) and Antares Pharma (ATRS).

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

Lisa D. Earnhardt, President, Chief Executive Officer, Director
Jeryl L. Hilleman, Chief Financial Officer
Richard E. Kaufman, Senior Vice President, Chief Operating Officer
David A. Lehman, General Counsel
Gwen Carscadden, Chief People Officer
Kieran T. Gallahue, Lead Director
Teresa L. Kline, Director
William Anthony Vernon, Director
Cynthia L. Lucchese, Independent Director
Dana G. Mead Jr., Independent Director

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by many different of retail and institutional investors. Top institutional investors include Mutual of America Capital Management LLC (0.31%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC. Company insiders that have sold Intersect ENT stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $30.60.

MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:		3.6 out of 5 ( )
Outperform Votes:		232 (Vote Outperform)
Underperform Votes:		93 (Vote Underperform)
Total Votes:		325

MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	2 Hold Ratings, 8 Buy Ratings
Consensus Rating:	Buy (Score: 2.80)
Consensus Price Target:	$27.11 (11.40% downside)

Consensus Price Target History for Intersect ENT (NASDAQ:XENT)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/13/2017	Canaccord Genuity	Boost Price Target	Buy	$32.00 -> $37.00	Low
9/11/2017	Bank of America Corporation	Boost Price Target	Buy	$33.00 -> $40.00	High
8/22/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	Low
8/2/2017	Deutsche Bank AG	Set Price Target	Buy	$27.00 -> $31.00	High
8/2/2017	Northland Securities	Reiterated Rating	Hold	$25.00	High
5/10/2017	William Blair	Reiterated Rating	Outperform		Low
5/3/2017	Wedbush	Boost Price Target	Outperform -> Outperform	$25.00 -> $26.00	High
12/6/2016	Guggenheim	Initiated Coverage	Buy	$20.00	N/A
11/4/2016	Leerink Swann	Reiterated Rating	Outperform	$21.00 -> $14.00	N/A
11/2/2016	J P Morgan Chase & Co	Downgrade	Overweight -> Neutral	$25.00 -> $16.00	N/A
8/4/2016	BTIG Research	Reiterated Rating	Hold	$14.00	N/A
3/24/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$29.00	N/A

(Data available from 10/20/2015 forward)

Earnings History for Intersect ENT (NASDAQ:XENT)

Earnings by Quarter for Intersect ENT (NASDAQ:XENT)

Earnings History by Quarter for Intersect ENT (NASDAQ XENT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/31/2017		($0.20)					N/A
8/1/2017	Q2 2017	($0.19)	($0.08)	$22.62 million	$24.00 million	View	Listen
5/2/2017	Q1 2017	($0.25)	($0.23)	$19.39 million	$20.47 million	View	Listen
2/28/2017	Q416	($0.20)	($0.17)	$23.47 million	$24.20 million	View	Listen
11/2/2016	Q316	($0.27)	($0.22)	$17.80 million	$18.50 million	View	N/A
8/2/2016	Q216	($0.26)	($0.21)	$18.91 million	$19.30 million	View	N/A
5/5/2016	Q116	($0.29)	($0.29)	$16.92 million	$16.69 million	View	N/A
2/23/2016	Q415	($0.25)	($0.20)	$18.36 million	$18.80 million	View	Listen
11/4/2015	Q315	($0.29)	($0.35)	$14.80 million	$14.20 million	View	N/A
8/5/2015	Q215	($0.26)	($0.23)	$14.74 million	$15.20 million	View	N/A
5/6/2015	Q115	($0.33)	($0.23)	$13.00 million	$13.37 million	View	N/A
2/26/2015	Q414	($0.29)	($0.16)	$12.20 million	$13.40 million	View	N/A
11/5/2014	Q314	($0.35)	($0.32)	$8.20 million	$9.10 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Intersect ENT (NASDAQ:XENT)

2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.46)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	3	($0.26)	($0.22)	($0.24)
Q2 2017	3	($0.19)	($0.19)	($0.19)
Q3 2017	3	($0.26)	($0.17)	($0.21)
Q4 2017	3	($0.17)	($0.06)	($0.13)
Q1 2018	2	($0.16)	($0.08)	($0.12)
Q2 2018	2	($0.12)	($0.11)	($0.12)
Q3 2018	2	($0.14)	($0.11)	($0.13)
Q4 2018	2	($0.14)	($0.06)	($0.10)

(Data provided by Zacks Investment Research)

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 83.12%

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/16/2017	Lisa D Earnhardt	Insider	Sell	20,000	$28.37	$567,400.00
10/4/2017	Jeryl L Hilleman	CFO	Sell	12,833	$29.96	$384,476.68
9/25/2017	Richard E Kaufman	COO	Sell	13,639	$28.97	$395,121.83
9/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$30.19	$603,800.00
9/5/2017	Jeryl L Hilleman	CFO	Sell	12,833	$31.05	$398,464.65
8/28/2017	Richard E Kaufman	COO	Sell	22,425	$30.22	$677,683.50
8/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$30.79	$615,800.00
8/4/2017	Jeryl L Hilleman	CFO	Sell	12,833	$29.00	$372,157.00
7/25/2017	Richard E Kaufman	COO	Sell	12,500	$28.25	$353,125.00
7/17/2017	Lisa D Earnhardt	Insider	Sell	20,000	$29.03	$580,600.00
7/10/2017	Jeryl L Hilleman	CFO	Sell	12,835	$27.18	$348,855.30
6/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$26.10	$522,000.00
5/22/2017	Richard E Kaufman	COO	Sell	20,000	$22.87	$457,400.00
5/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$22.98	$459,600.00
4/20/2017	Richard E Kaufman	COO	Sell	1,250	$17.25	$21,562.50
4/17/2017	Lisa D Earnhardt	Insider	Sell	20,000	$16.06	$321,200.00
3/15/2017	Lisa D Earnhardt	Insider	Sell	20,000	$15.02	$300,400.00
10/20/2016	Richard E Kaufman	COO	Sell	3,603	$16.58	$59,737.74
10/17/2016	Lisa D Earnhardt	Insider	Sell	400	$18.00	$7,200.00
9/7/2016	Amy Wolbeck	VP	Sell	28,664	$15.83	$453,751.12
9/6/2016	James Stambaugh	VP	Sell	4,000	$16.00	$64,000.00
8/3/2016	James Stambaugh	VP	Sell	3,977	$17.00	$67,609.00
7/18/2016	James Stambaugh	VP	Sell	5,000	$15.33	$76,650.00
6/13/2016	James Stambaugh	VP	Sell	500	$14.38	$7,190.00
5/16/2016	Kieran Gallahue	Director	Buy	8,000	$12.64	$101,120.00
4/27/2016	Amy Wolbeck	VP	Sell	2,000	$20.01	$40,020.00
4/20/2016	Richard E Kaufman	COO	Sell	3,603	$18.86	$67,952.58
4/18/2016	Lisa D Earnhardt	CEO	Sell	28,500	$18.69	$532,665.00
3/21/2016	Richard E Kaufman	COO	Sell	3,603	$16.51	$59,485.53
3/15/2016	Lisa D Earnhardt	CEO	Sell	9,000	$18.01	$162,090.00
3/14/2016	Frederic H Moll	Director	Sell	1,299	$18.53	$24,070.47
3/8/2016	Frederic H Moll	Director	Sell	601	$18.56	$11,154.56
2/22/2016	Richard E Kaufman	COO	Sell	3,603	$18.65	$67,195.95
1/21/2016	Richard E. Kaufman	COO	Sell	7,206	$17.93	$129,203.58
1/15/2016	Lisa D. Earnhardt	CEO	Sell	12,500	$19.26	$240,750.00
12/15/2015	Lisa D Earnhardt	CEO	Sell	6,820	$19.85	$135,377.00
11/16/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.00	$122,724.00
10/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$18.72	$127,632.96
9/15/2015	Lisa D Earnhardt	CEO	Sell	6,818	$25.99	$177,199.82
9/11/2015	Frederic H Moll	Director	Sell	10,000	$25.21	$252,100.00
8/17/2015	Lisa D Earnhardt	CEO	Sell	6,818	$28.51	$194,381.18
7/20/2015	James Stambaugh	VP	Sell	12,000	$30.52	$366,240.00
7/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.62	$572,199.16
6/15/2015	Lisa D Earnhardt	CEO	Sell	19,318	$29.30	$566,017.40
5/8/2015	James Stambaugh	VP	Sell	2,785	$23.87	$66,477.95
4/13/2015	Amy Wolbeck	VP	Sell	16,000	$26.25	$420,000.00
4/1/2015	James Stambaugh	VP	Sell	8,343	$25.50	$212,746.50
3/16/2015	Lisa D Earnhardt	Insider	Sell	19,318	$23.56	$455,132.08
3/11/2015	Amy Wolbeck	VP	Sell	8,000	$23.06	$184,480.00
3/9/2015	James Stambaugh	VP	Sell	8,343	$23.02	$192,055.86
2/17/2015	Lisa D Earnhardt	Insider	Sell	19,318	$22.69	$438,325.42
2/12/2015	Amy Wolbeck	VP	Sell	8,000	$22.12	$176,960.00
2/2/2015	James Stambaugh	VP	Sell	8,343	$20.98	$175,036.14
1/26/2015	Robert H Binney Jr	VP	Sell	6,300	$21.18	$133,434.00
9/11/2014	Cynthia L Lucchese	Director	Buy	5,000	$17.11	$85,550.00

(Data available from 1/1/2013 forward)

Headline Trends for Intersect ENT (NASDAQ:XENT) Latest Headlines for Intersect ENT (NASDAQ:XENT)

Source:

Date	Headline
	Intersect ENT, Inc. (XENT) Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share www.americanbankingnews.com - October 18 at 11:28 AM
	Commit To Buy Intersect ENT At $25, Earn 16.6% Annualized Using Options www.nasdaq.com - October 18 at 10:52 AM
	Intersect ENT, Inc. (XENT) Insider Lisa D. Earnhardt Sells 20,000 Shares www.americanbankingnews.com - October 17 at 7:26 PM
	Intersect ENT, Inc. Forecasted to Earn Q2 2018 Earnings of ($0.11) Per Share (XENT) www.americanbankingnews.com - October 17 at 11:46 AM
	Intersect ENT to Report Third Quarter 2017 Financial Results finance.yahoo.com - October 17 at 9:24 AM
	Ocular Therapeutix (OCUL) vs. Intersect ENT (XENT) Head-To-Head Comparison www.americanbankingnews.com - October 14 at 12:36 PM
	ETFs with exposure to Intersect ENT, Inc. : October 10, 2017 finance.yahoo.com - October 11 at 9:43 AM
	ETFs with exposure to Intersect ENT, Inc. : October 10, 2017 finance.yahoo.com - October 11 at 9:43 AM
	The Zacks Analyst Blog Highlights: IDEXX Laboratories, Steris, K2M Group Holdings, Tandem Diabetes Care and Intersect ENT finance.yahoo.com - October 11 at 9:43 AM
	Intersect ENT, Inc. :XENT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 finance.yahoo.com - October 10 at 8:31 AM
	INTERSECT ENT INC www.finanznachrichten.de - October 9 at 9:32 AM
	Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant finance.yahoo.com - October 9 at 9:32 AM
	Intersect ENT, Inc. (XENT) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - October 7 at 2:52 AM
	Intersect ENT (XENT) and Its Competitors Financial Analysis www.americanbankingnews.com - October 6 at 4:10 PM
	Insider Selling: Intersect ENT Inc (XENT) CFO Sells 12,833 Shares of Stock www.americanbankingnews.com - October 5 at 7:26 PM
	The Saga to Revoke Obamacare Continues: 3 MedTech Picks - Nasdaq www.nasdaq.com - October 5 at 6:34 PM
	The Saga to Revoke Obamacare Continues: 3 MedTech Picks finance.yahoo.com - October 5 at 6:34 PM
	Intersect ENT, Inc. (XENT) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - October 5 at 9:50 AM
	Intersect ENT, Inc. (XENT) Expected to Announce Earnings of -$0.20 Per Share www.americanbankingnews.com - October 2 at 8:32 AM
	Insider Selling: Intersect ENT, Inc. (XENT) COO Sells 13,639 Shares of Stock www.americanbankingnews.com - September 27 at 7:46 PM
	Intersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : September 21, 2017 finance.yahoo.com - September 23 at 12:13 PM
	Intersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : September 22, 2017 finance.yahoo.com - September 23 at 12:13 PM
	Canaccord Genuity Reiterates "Buy" Rating for Intersect ENT, Inc. (XENT) www.americanbankingnews.com - September 13 at 3:34 PM
	Analysts Issue Forecasts for Intersect ENT, Inc.'s Q3 2017 Earnings (XENT) www.americanbankingnews.com - September 13 at 7:42 AM
	Intersect ENT (XENT) Reports Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety ... - StreetInsider.com www.streetinsider.com - September 12 at 12:30 PM
	Intersect ENT, Inc. (XENT) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 12 at 3:06 AM
	Intersect ENT, Inc. (XENT) Price Target Increased to $40.00 by Analysts at Bank of America Corporation www.americanbankingnews.com - September 11 at 8:22 AM
	Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and ... - Business Wire (press release) www.businesswire.com - September 10 at 9:59 AM
	Intersect ENT Announces Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant finance.yahoo.com - September 10 at 9:59 AM
	Jeryl L. Hilleman Sells 12,833 Shares of Intersect ENT, Inc. (XENT) Stock www.americanbankingnews.com - September 6 at 8:26 PM
	Intersect ENT, Inc. (XENT) COO Sells $677,683.50 in Stock www.americanbankingnews.com - August 29 at 7:18 PM
	Intersect ENT, Inc. (XENT) Earns Buy Rating from Piper Jaffray Companies www.americanbankingnews.com - August 22 at 4:28 PM
	Intersect ENT, Inc. (XENT) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - August 18 at 2:42 PM
	Insider Selling: Intersect ENT, Inc. (XENT) Insider Sells 20,000 Shares of Stock www.americanbankingnews.com - August 17 at 7:38 PM
	ETFs with exposure to Intersect ENT, Inc. : August 14, 2017 finance.yahoo.com - August 15 at 8:31 AM
	-$0.20 Earnings Per Share Expected for Intersect ENT, Inc. (NASDAQ:XENT) This Quarter www.americanbankingnews.com - August 7 at 6:26 PM
	FY2017 EPS Estimates for Intersect ENT, Inc. Raised by William Blair (NASDAQ:XENT) www.americanbankingnews.com - August 4 at 10:00 AM
	Intersect ENT, Inc. Forecasted to Post Q3 2017 Earnings of ($0.26) Per Share (NASDAQ:XENT) www.americanbankingnews.com - August 4 at 7:16 AM
	Q3 2017 EPS Estimates for Intersect ENT, Inc. Decreased by Analyst (XENT) www.americanbankingnews.com - August 4 at 7:16 AM
	Leerink Swann Equities Analysts Lift Earnings Estimates for Intersect ENT, Inc. (NASDAQ:XENT) www.americanbankingnews.com - August 3 at 4:40 PM
	Intersect ENT Reports Second Quarter 2017 Results - Business Wire (press release) www.businesswire.com - August 3 at 9:05 AM
	Edited Transcript of XENT earnings conference call or presentation 1-Aug-17 8:30pm GMT finance.yahoo.com - August 3 at 9:05 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Stock Rating Reaffirmed by Canaccord Genuity www.americanbankingnews.com - August 2 at 4:38 PM
	Intersect ENT, Inc. (XENT) Stock Rating Reaffirmed by Northland Securities www.americanbankingnews.com - August 2 at 2:02 PM
	Investor Network: Intersect ENT Inc to Host Earnings Call finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT Reports Second Quarter 2017 Results finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT reports 2Q loss finance.yahoo.com - August 2 at 8:54 AM
	Intersect ENT, Inc. (NASDAQ:XENT) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS www.americanbankingnews.com - August 1 at 10:46 PM
	ETFs with exposure to Intersect ENT, Inc. : July 31, 2017 finance.yahoo.com - August 1 at 8:01 AM
	Intersect Looks To Boost Position In ENT Implant Market, Driving Stock Up seekingalpha.com - July 29 at 8:51 AM